NEW YORK—Johnson & Johnson (NYSE: JNJ), a multinational healthcare giant based in the US, has announced a definitive agreement to acquire V-Wave Ltd., an innovative Israeli medical device company. The acquisition is set to bolster J&J’s MedTech segment with an upfront payment of USD 600 million and potential milestone-based payments totaling up to USD 1.1 billion, subject to regulatory and commercial achievements. The transaction is anticipated to conclude in the fourth quarter of 2024, with V-Wave integrating into J&J’s medical technology division.
Founded in 2009, V-Wave has been dedicated to the advancement of medical devices addressing heart failure and other cardiovascular diseases (CVDs). The company’s flagship product, the Ventura Interatrial Shunt (IAS), is an implant designed for patients diagnosed with heart failure with reduced ejection fraction (HFrEF). The IAS operates by creating a shunt between the left and right atria, thereby reducing the elevated left atrial pressure associated with congestive heart failure. This minimally invasive procedure has the potential to significantly decrease cardiovascular events and hospitalizations related to heart failure.
The IAS has garnered significant recognition, including a breakthrough device designation by the US FDA in 2019 and a CE mark in 2020, underscoring its innovative status within the medical device industry. Michael Bodner, J&J’s group president for heart recovery and intravascular lithotripsy, will oversee V-Wave’s operations following the acquisition, ensuring the continued development and commercialization of its life-saving technologies.- Flcube.com
